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The mTOR pathway is a key regulator of multiple cellular signaling pathways and is a poten-
tial target for therapy. We have previously developed two hormone-resistant sub-lines of
the MCF-7 human breast cancer line, designatedTamC3 andTamR3, which were character-
ized by reduced mTOR signaling, reduced cell volume, and resistance to mTOR inhibition.
Here, we show that these lines exhibit increased sensitivity to carboplatin, oxaliplatin, 5-
fluorouracil, camptothecin, doxorubicin, paclitaxel, docetaxel, and hydrogen peroxide. The
mechanisms underlying these changes have not yet been characterized but may include
a shift from glycolysis to mitochondrial respiration. If this phenotype is found in clini-
cal hormone-resistant breast cancers, conventional cytotoxic therapy may be a preferred
option for treatment.
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INTRODUCTION
The mTOR pathway is a key regulator of multiple cell signal-
ing pathways, integrating growth factors, nutrients, energy, and
stress (1). In breast cancer cells, mTOR signaling is linked through
phosphatidylinositol 3-kinase (PI3K) and Akt/protein kinase B
(PKB) (2) to signaling from external cellular receptors such as
EGFR. Increased signaling through the mTOR pathway has been
proposed to control distinct regulatory motifs that promote a pro-
invasion translational program (3, 4) and to control important
mechanisms for endocrine resistance (5). In the MCF-7 breast
cancer cell line, mTOR activity is thought to be responsible for
the constitutive activity of Akt, and inhibition of mTOR activ-
ity restores response to the antiestrogen tamoxifen (6). It was
therefore surprising to find, during the course of selecting cul-
tures of MCF-7 cells for resistance to tamoxifen or to estrogen
deprivation, two cell lines (TamC3 and TamR3, respectively) that
had reduced mTOR signaling, as shown by reduced phosphory-
lation of the downstream enzymes Akt/PKB and p70S6K, as well
as increased resistance to the mTOR inhibitors rapamycin and
everolimus (7, 8) and to the dual PI3K/mTOR inhibitors NVP-
BEZ235 and GSK2126458 (9). The TamC3 and TamR3 resistant
cell lines were distinguished from the parental line by having
reduced cellular DNA contents (ploidies), strongly reduced modal
cell volumes, slightly reduced cell cycle times, and altered signaling
pathway usage (7). The differing ploidies suggest that they arose
from expansion of minor subpopulations of the original MCF-7
cell line rather from metabolic adaptation of the parental line. The
TamC3 and TamR3 sub-lines also showed increased expression
of ER, progesterone receptors (PR), and epidermal growth factor
receptor-2 (EGFR2; HER2) (7, 9, 10). Here, we have investigated
the properties of these two cell lines that might explain their behav-
ior. We have measured their sensitivity, in comparison to that of
the parental line, to DNA damaging anticancer drugs, mitotic poi-
sons, or oxidative damage. We have also determined whether the
phenotype is associated with decreased glycolysis and increased
mitochondrial respiration.
MATERIALS AND METHODS
CELL CULTURE
Culture conditions have been described previously (7); MCF-7 was
purchased from the American Type Culture Collection (ATCC).
The TamR3 cell line was generated by growth of MCF-7 cells
in phenol-red-free RPMI containing 10% charcoal-stripped fetal
bovine serum (Invitrogen, Auckland, New Zealand), over a period
of 3 months to progressively increasing concentrations of tamox-
ifen (1 nM to 1µM in ethanol) and then maintaining them for
>15 months in 1µM tamoxifen. The TamC3 cell line was gen-
erated by exposure of MCF-7 cells for >16 months to the above
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FIGURE 1 | Comparison of basal levels of Akt- and
p70S6K-phosphorylation in the MCF-7 line and its sub-lines and drug
sensitivity to 4-hydroxytamoxifen and mTOR inhibitors. (A) Effects of
4-hydroxytamoxifen on the proliferation of MCF-7 parental, TamC3, and TamR3
cell lines. The cell lines were exposed to 4-hydroxytamoxifen (111 nM) for
4 days and cell proliferation was measured by a thymidine incorporation assay.
*Significantly different from MCF-7 parental line (Holm–Sidak test; p<0.05).
(B) Relative expression of phosphorylated p70S6K and Akt, and total p70S6K
and Akt in MCF-7, TamC3, and TamR3 cell lines. Actin is shown as a loading
control. (C) IC50 values for rapamycin and everolimus in MCF-7 parental,
TamC3, and TamR3. Cells were treated with rapamycin or everolimus for
4 days with [3H]-thymidine added for the last 6 h. The highest drug
concentration is depicted where 50% growth inhibition was not reached. Bars
indicate SE (duplicate experiments).
growth medium but lacking tamoxifen. Both TamC3 and TamR3
cell lines are cross-resistant to 4-hydroxytamoxifen (Figure 1A).
All experiments were carried out on cells grown in their respective
growth media but without tamoxifen.
CHEMICALS AND REAGENTS
Propidium iodide, tamoxifen, camptothecin, doxorubicin,
hydrogen peroxide, cisplatin, carboplatin, oxaliplatin, pacli-
taxel, docetaxel, fluorouracil, bicinchoninic acid (BCA), 4-
hydroxytamoxifen, and tamoxifen were from Sigma (Auckland,
New Zealand).
MEASUREMENT OF DNA CONTENT FOR CELL CYCLE ANALYSIS
Cells (1× 106 cells) were grown in six-well plates and incubated
with inhibitors for 24 h. Cells were harvested, washed with 1%
FCS/phosphate-buffered saline (PBS), resuspended in 200µl of
PBS, fixed in 2 ml of ice-cold 100% ethanol, and stored overnight
at −20°C. The cells were washed and resuspended in 1 ml of 3%
FCS/PBS containing RNase (1µg/ml) and propidium iodide (PI)
(10µg/ml) for 30 min at room temperature. DNA content was
determined using forward scatter (FSC) intensity by PI staining
based on a total 30,000 acquired events by FACScan cytometry.
MEASUREMENT OF DNA DAMAGE
DNA damage was measured after harvesting cells, washing and
resuspended in 200µl of PBS, fixing in 2 ml of ice-cold 100%
ethanol, and storing overnight at −20°C. Cells were resuspended
in 1 ml of blocking buffer (1% FCS/PBS), and incubated with
antibody to γ-H2AX (phosphorylated Ser139) (Millipore, USA)
in blocking buffer (1:500 dilution) at room temperature for 2 h.
Cells were washed, incubated with goat anti-mouse Alex 488 Fab
fragment secondary antibody (Invitrogen, New Zealand) (1:400
in blocking buffer for 1 h, at room temperature; dark), washed
and resuspended in 1 ml of blocking buffer containing RNase
(1µg/ml) and propidium iodide (PI) (10µg/ml) for 30 min at
room temperature. Cells were analyzed in a Becton Dickinson
LSRII and profiles were analyzed with ModFit LT 3 software.
CELL PROLIFERATION ASSAY
Cell proliferation was measured using a thymidine incorpora-
tion assay in which 3,000 cells were seeded in 96-well plates in
the presence of varying concentrations of drugs for the indi-
cated number of days. Cell proliferation was measured either by
thymidine uptake assay (for 4-hydroxytamoxifen, everolimus, and
rapamycin) or sulforhodamine B colorimetric assay (for all other
inhibitors). Briefly, [3H] thymidine (0.04µCi) was added to each
well and plates were incubated for 5 h, after which the cells were
harvested onto glass–fiber filters using an automated TomTec har-
vester. Filters were incubated with Betaplate Scint and thymidine
incorporation was measured in a Trilux/Betaplate counter. Cell
proliferation was determined by the percentage incorporation of
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[3H]thymidine. All experiments were carried out in triplicate, and
repeated at least twice. The sulforhodamine B colorimetric assay,
which is based on the measurement of cellular protein content, was
used to measure cell density (11). After drug treatment for 3 days,
cells were fixed with 10% (wt/vol) trichloroacetic acid and stained
for 30 min, and the excess dye was removed by washing repeatedly
with 1% (vol/vol) acetic acid. The protein-bound dye was dissolved
in Tris base solution (10 mM) for optical density determination at
510 nm using a microplate reader. All experiments were done in
triplicate, and were repeated at least twice. Optimal cell densi-
ties were previously determined to select initial cell densities that
ensured that cells were in logarithmic phase for the experiments.
GLUCOSE UPTAKE
Cells (1× 106 cells) were grown in six-well plates and incubated
for 24 h. Cells were incubated with 1µCi (1µl) of 2-deoxy-d-[1-
3H]glucose (Perkin Elmer) in 1 ml of media for 20 min at 37°C.
The cells were washed two times with ice-cold PBS, and lysed in
1 ml of 1% SDS. Cell lysate 0.8 ml in 4.5 ml Ecoscint H (National
Diagnostics LS-275) was counted on a scintillation device for
1 min. All experiments were done in triplicates wells, and repeated
at least two times.
MEASUREMENT OF REACTIVE OXYGEN SPECIES
Intracellular reactive oxygen species (ROS) were detected with
the cell permeable fluorescent probe 5-(and 6-)-chloromethyl-
2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) (Life
Technologies). Cells (1× 106) were grown in six-well plates
and incubated for 24 h. Cells were incubated with 10µM CM-
H2DCFDA in PBS with 2% FCS for 30 min in the dark at 37°C.
Cells were then trypsinized and analyzed in a Becton Dickin-
son LSRII and data were analyzed with FlowJo software. All
experiments were done in 10 wells, and repeated at least two times.
MEASUREMENT OF MITOCHONDRIAL REDUCTIVE ACTIVITY
Mitochondria activity is measured by Alamar Blue assay (Life
Technologies). Superoxide dismutase (SOD) was measured using
a water-soluble tetrazolium salt (WST-1) (purchased from Roche)
(12). The stable tetrazolium salt WST-1 is cleaved to a soluble
formazan by a complex cellular mechanism that occurs primarily
at the cell surface. This bioreduction is largely dependent on the
glycolytic production of NAD(P)H in viable cells. Therefore, the
amount of formazan dye formed directly correlates to the number
of metabolically active cells in the culture. All experiments were
done in 10 wells, and repeated at least two times.
MEASUREMENT OF L-LACTATE
Cells (1× 105) were seeded the previous day, the culture medium
was replaced with 500µl growth medium and the cells were grown
for 4 h at 37°C. Medium was removed from cells and lactate lev-
els in the extracellular medium were measured using the l-lactate
Colorimetric Assay Kit (Abcam, Cambridge, MA, USA). Lactate
levels were normalized to final cell counts. All experiments were
done in five wells, and repeated at least two times.
MEASUREMENT OF CISPLATIN UPTAKE
Uptake of cisplatin by MCF-7 parental and sub-lines utilized
inductively coupled plasma spectrometry (ICP-MS; carried out
at LabPLUS, Auckland, New Zealand). Cells were incubated in
transport buffer (125 mM NaCl, 4.8 mM KCl, 5.6 mM d-glucose,
1.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, and 25 mM
HEPES pH 7.4) containing cisplatin (30µM) for 30 min at 37°C
in 5% CO2. Following incubation, cells were washed once with
ice-cold PBS, twice with PBS containing 10 mM EDTA, and lysed
in 70% nitric acid at room temperature for at least 2 h. Cellular
protein content was quantified using previously described method
(13). All experiments were done in duplicate wells, and repeated
at least two times.
MAMMOSPHERE FORMATION
MCF-7 parental and sub-lines were trypsinized from the mono-
layer culture and cell suspensions were then seeded in 96-well
non-tissue culture treated plates, with 1,000 cells per well in 8 repli-
cates per experiment. Cells were grown in MammoCult® medium
(Stem Cell Technologies), and were kept at 37°C with 5% CO2.
Mammospheres were counted after 7 days. All experiments were
repeated at least two times.
IMMUNOBLOTTING
Parental MCF-7 cells and the variants TamC3 and TamR3 were
grown to logarithmic phase, washed twice with ice-cold PBS
and lysed in SDS lysis buffer according to the manufacturer’s
protocol (Cell Signaling Technology, Danvers, MA, USA). Pro-
tein concentration was quantified using the BCA protein assay
reagent bicinchoninic acid (Sigma). Cell lysates containing 20µg
of protein were separated by SDS-PAGE gel electrophoresis and
transferred to PVDF membranes (Millipore). Membranes were
immunoblotted with antibodies against phospho-Akt (S473), total
Akt, phospho-70S6K (T389), total p70S6K (all from Cell Signal-
ing Technology), and actin (Millipore), using SuperSignal West
Pico (Thermo Scientific, Waltham, MA, USA) or ECL advance
(GE Healthcare, Auckland, New Zealand). Antibody reactivity was
visualized using the chemiluminescence detection system by Fuji-
film Las-3000. Densitometry was performed using ImageJ. The
relative intensity of phosphorylated proteins was normalized using
actin as the standard. The fold change was then calculated using
MCF-7 as standard reference.
STATISTICAL ANALYSIS
Data were analyzed using a one-way ANOVA.
RESULTS
REDUCED mTOR PATHWAY SIGNALING AND SENSITIVITY TO mTOR
INHIBITORS
The TamC3 and TamR3 lines showed increased resistance, in com-
parison to the parental line, to 4-hydroxytamoxifen (Figure 1A).
They also showed reduced phosphorylation of the downstream
enzymes Akt/PKB and p70S6K (Figure 1B) and reduced sensitivity
to mTOR inhibitors rapamycin and everolimus (Figure 1C).
COMPARISON OF SENSITIVITY TO THERAPEUTIC AGENTS
The sensitivity of MCF-7, TamC3, and TamR3 to a range of
chemotherapeutic agents was tested (Figures 2 and 3). These
agents included the topoisomerase I inhibitor camptothecin, the
topoisomerase II inhibitor doxorubicin, the DNA intrastrand
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FIGURE 2 | Growth inhibitory concentrations for MCF-7 and its sub-lines
exposed to different drugs IC30 values (30% inhibition of growth) are
shown for experiments for taxanes and 5-fluorouracil where 50% growth
inhibition was not reached, and IC50 (50% inhibition of growth) for all of
the other agents. Cells were treated with drugs for 3 days and cell
proliferation was measured by the sulforhodamine B assay. Bars indicate SE
in two independent experiments. *Significantly different from MCF-7 parental
line (p<0.05).
cross-linkers cisplatin, carboplatin, and oxaliplatin, the mitotic
inhibitors paclitaxel and docetaxel, and the thymidylate synthase
inhibitor 5-fluorouracil. Sensitivity to the oxidizing agent sodium
peroxide as also measured. The increased sensitivities of TamC3
and TamR3, in comparison to the parental line, as measured by
IC50 ratios parental/TamC3 and parental/TamR3, were, respec-
tively, 19- and 29-fold for camptothecin, 9- and 10-fold for
doxorubicin, 12- and 12-fold for cisplatin, 7.8- and 6.6-fold for
carboplatin, 78- and 183-fold for oxaliplatin, 18- and 27-fold
for 5-fluorouracil, 3.5- and 4-fold for paclitaxel, 4.4- and 9.4-fold
for docetaxel, and 10- and 11-fold for hydrogen peroxide.
COMPARISON OF INDUCTION OF DNA DAMAGE BY CISPLATIN AND
OXALIPLATIN
The increased sensitivity of TamC3 and TamR3 to cisplatin was
further investigated. Since resistance has been associated with
decreased cellular uptake or increased drug efflux (14), we mea-
sured cell-associated drug (Figure 4A) and found it to be 50%
significantly higher in TamC3 (p< 0.05) but not in TamR3. How-
ever, these changes did not explain the 12-fold increase in drug
sensitivity. Flow cytometry, combining measurement of DNA con-
tent and of γ-phosphorylation of H2AX as an indication of DNA
damage, was used to compare responses to cisplatin and oxaliplatin
after 2 h. In comparison to the parental line, both TamC3 and
TamR3 showed increased sensitivity to γ-H2AX induction, and
increased S-phase arrest (Figure 4B). Increased γ-H2AX induc-
tion was found predominantly in S-phase cells (Figure 5) and
the increases were consistent with the observed decreases in IC50
values (Figure 2).
COMPARISON OF CELLULAR ENERGY UTILIZATION
Since chemoresistance is associated with increased glucose uptake
and glycolysis (15–17), we measured glucose uptake using 2-
deoxy-d-[1-3H]-glucose and found it to be significantly reduced in
TamC3 and TamR3 compared to the parental line (Figure 6A). We
also measured the lactate concentration in the culture medium
as a marker for glycolysis and found it to be significantly lower
for TamC3 and TamR3 than for the parental line (Figure 6B).
We then determined whether the reduced glucose uptake and
glycolysis in TamC3 and TamR3 was accompanied by increased
mitochondrial respiration. We used Alamar Blue, an oxidation–
reduction sensitive dye that detects oxidation by all the elements
of the electron transport chain, as a measure of mitochondrial
activity. TamC3 and TamR3 showed increased staining in com-
parison to the parental line, indicative of increased mitochondrial
utilization, in comparison to the parental line (Figure 6C).
Increased mitochondrial activity is associated with increased
ROS production (18). We therefore determined cellular ROS
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FIGURE 3 | Growth inhibitory effect of drugs on MCF-7 and its sub-lines. Cells were treated with drugs for 3 days and cell proliferation was measured by
the sulforhodamine B assay. Bars indicate SE in two independent experiments. *Significantly different from MCF-7 parental line (p<0.05).
FIGURE 4 | Cisplatin uptake and S-phase cell cycle arrest in the
MCF-7 and its sub-lines. (A) Comparison of cisplatin uptake by
MCF-7 parental and its sub-lines. (B) Cell cycle proportions (upper
panel) in S-phase (lower panel) of MCF-7 cell lines treated with
50µM cisplatin for 24 h analyzed by flow cytometry. Results were
averaged from duplicate samples from one of two independent
experiments. *Significant difference from treatment control
(p<0.05).
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FIGURE 5 | Induction of DNA damage in the MCF-7 and its sub-lines.
Induction of γ-H2AX phosphorylation following exposure to cisplatin or
oxaliplatin for 2 h. MCF-7 parental and derived TamC3 and TamR3 sub-lines
were either untreated or exposed cisplatin (50µM) or oxaliplatin (50µM)
then fixed, stained, and assessed by flow cytometry for γ-H2AX staining.
Cellular immunofluorescence (anti-γ-H2AX antibody; y -axis) is plotted
against DNA content (propidium iodide staining; x -axis). The upper half
(marked) represents high γ-H2AX phosphorylation and the proportion of
the total is indicated. Representative images of two independent
experiments are shown.
concentrations by flow cytometry using the redox-sensitive DCF-
DA fluorescent probe; both TamC3 and TamR3 showed almost
twice the level of ROS generated by the parental line (Figure 6D).
Since cellular production of ROS is generally associated with
induction of the intracellular ROS-scavenging system SOD, we
a determined cellular SOD content by cleavage of the tetrazolium
salt WST-1; this was found to be increased in TamC3 and TamR3
cells as compared to the parental cells (Figure 6E).
Stem cell-like properties of breast cancer cells are known
to be associated with reduced dependence on mitochondria,
as shown by decreased production of ROS and increased glu-
cose metabolism. Since the formation of mammospheres is an
indication of stem cell-like character (19, 20), we hypothesized that
the increased mitochondrial activity of TamC3 and TamR3 would
be associated with a decreased ability to form mammospheres and
therefore compared the ability of MCF-7, TamC3, and TamR3
to form mammospheres. As shown in Figure 6A, TamC3 and
TamR3 were less efficient than MCF-7 parental cells in mammos-
phere formation (Figure 7A); they formed only compact spheroids
(Figure 7B).
DISCUSSION
Our results point to the existence of sub-lines of the MCF-7 breast
cancer cell line where resistance to 4-hydroxytamoxifen is cou-
pled to increased resistance to inhibitors of the mTOR pathway
but increased sensitivity to a variety of cytotoxic anticancer drugs.
These properties are consistent with those reported for a number
of other hormone-resistant breast cancer lines, where resistance to
inhibitors of the mTOR/Akt pathway is generally associated with
increased resistance to a broad variety of cytotoxic agents (21). It
should be noted, however, that a hormone-resistant triple-negative
breast cancer cell line shows increased sensitivity to cisplatin (22).
Increased utilization of the PI3K/mTOR pathway in ER+ breast
cancer has been associated not only with endocrine resistance
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FIGURE 6 | Comparison of cellular energy utilization. (A) Uptake of
2-deoxy-d-[1-3H]glucose by MCF-7 parental, TamC3, and TamR3 cells.
(B) Lactate concentration in culture medium of MCF-7 parental, TamC3,
or TamR3 cells, measured spectrophotometrically. (C) Metabolic rate of
MCF-7 parental, TamC3, and TamR3 cells, as measured by Alamar Blue
assay. (D) ROS concentration in MCF-7 parental, TamC3, and TamR3
cells as measured by DCF-DA fluorescence. (E) SOD activity in MCF-7
parental, TamC3, and TamR3 cells, as measured by WST assay.
*Significantly different from MCF-7 parental line (p<0.05). Results
from representative experiments were shown as the mean±SE from
the indicated replicates detailed in the Section “Materials and
Methods.”
FIGURE 7 | Mammospheres formation in MCF-7 parental,TamC3, andTamR3 cells. (A) Mammosphere formation efficiency in MCF-7 parental, TamC3, and
TamR3 cells. (B) Mammospheres morphology of MCF-7 parental (ascini), TamC3, and TamR3 cells (compact spheroid). *Significantly different from MCF-7
parental line (p<0.05).
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but also with resistance to a variety of cytotoxic drugs (23, 24).
In contrast, several studies have shown that inhibition of mTOR
sensitizes tumor cells to cisplatin, paclitaxel, and doxorubicin (25–
28). The latter results are consistent the present results showing
decreased utilization of the PI3K/mTOR pathway to be associated
with increased sensitivity to cisplatin, paclitaxel, and doxorubicin.
To this apparent paradox can be added our more recent find-
ing that continued passage of the TamC3 and TamR3 sub-lines
resulted in levels of phosphorylation of p70S6K and Akt that were
similar to those of the parental MCF-7 cell line (9). However, these
later passages retained increased mitochondria respiration, resis-
tance to mTOR inhibitors, and sensitivity to a variety of cytotoxic
agents (unpublished data). Like earlier passages, they also show
smaller cell volumes than those of the parental line. One pos-
sible interpretation of these results is that the level of Akt and
p70S6K phosphorylation does not accurately reflect the degree of
utilization of the PI3K/mTOR.
In attempting to find a mechanistic basis for the TamC3/TamR3
phenotype, it should be noted that the TamR3 and TamC3 sub-
lines are distinguished from the parental line by their degree of
mitochondrial activity; the increased production of reactive oxy-
gen intermediates, as measured by Alamar Blue (NADH/FADH
conversion) and WST-1 (superoxide production) assays, is consis-
tent with TamR3 and TamC3 having an increased dependence on
mitochondrial metabolism in comparison with the parental line.
The reduced 2-deoxyglucose uptake and reduced lactate produc-
tion also suggest a shift toward increased mitochondrial respira-
tion. The reduced stem cell-like character of TamR3 and TamC3
(Figure 6) also reflects an increased dependence on mitochon-
drial metabolism, as demonstrated by other groups (19, 20). One
factor that could be important in stimulating mitochondrial respi-
ration is the p53 protein (29), which is expressed in the MCF-7 line
(30). The p53 pathway is known to link cellular responses to DNA
damage, mitotic damage, and oxidative stress to the induction of
cell cycle arrest and/or apoptosis (31). It was clear in the studies
with cisplatin that the TamC3 and TamR3 sub-lines were much
more sensitive than the parental line to the induction increased
γ-phosphorylation of H2AX (Figure 4); the ATM kinase is respon-
sible for γ-phosphorylation of H2AX is also responsible activation
of p53 (32, 33).
In conclusion, we have demonstrated in MCF-7 cells that long-
term deprivation of estrogen or exposure to tamoxifen can lead to
the emergence of a hormone-resistant phenotype with dramati-
cally increased sensitivity to a variety of cytotoxic drugs. If clinical
hormone-resistant breast cancers with phenotypes similar those
described here for TamR3 and TamC3 can be identified, therapies
could be based on their increased susceptibility to conventional
cytotoxic anticancer drugs.
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